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Molecular response to treatment redefines all prognostic factors
in children and adolescents with B-cell precursor acute
lymphoblastic leukemia: results in 3184 patients of the
AIEOP-BFM ALL 2000 study
Abstract
The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute
Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the first time introduced standardized
quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell
receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD), at 2 time points (TPs),
to stratify patients in a large prospective study. Patients with precursor B (pB) ALL (n = 3184) were
considered MRD standard risk (MRD-SR) if MRD was already negative at day 33 (analyzed by 2
markers, with a sensitivity of at least 10(-4)); MRD high risk (MRD-HR) if 10(-3) or more at day 78 and
MRD intermediate risk (MRD-IR): others. MRD-SR patients were 42% (1348): 5-year event-free
survival (EFS, standard error) is 92.3% (0.9). Fifty-two percent (1647) were MRD-IR: EFS 77.6% (1.3).
Six percent of patients (189) were MRD-HR: EFS 50.1% (4.1; P < .001). PCR-MRD discriminated
prognosis even on top of white blood cell count, age, early response to prednisone, and genotype. MRD
response detected by sensitive quantitative PCR at 2 predefined TPs is highly predictive for relapse in
childhood pB-ALL. The study is registered at http://clinicaltrials.gov: NCT00430118 for BFM and
NCT00613457 for AIEOP.
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The Associazione Italiana di Ematologia On-
cologia Pediatrica and the Berlin-Frankfurt-
Mu¨nster Acute Lymphoblastic Leukemia
(AIEOP-BFM ALL 2000) study has for the
first time introduced standardized quantita-
tive assessment of minimal residual disease
(MRD) based on immunoglobulin and T-cell
receptor gene rearrangements as polymer-
ase chain reaction targets (PCR-MRD), at
2 time points (TPs), to stratify patients in a
large prospective study. Patients with pre-
cursor B (pB) ALL (n 3184) were consid-
ered MRD standard risk (MRD-SR) if MRD
was already negative at day 33 (analyzed by
2 markers, with a sensitivity of at least 104);
MRD high risk (MRD-HR) if 103 or more at
day 78 and MRD intermediate risk (MRD-IR):
others. MRD-SR patients were 42% (1348):
5-year event-free survival (EFS, standard
error) is 92.3% (0.9). Fifty-two percent (1647)
were MRD-IR: EFS 77.6% (1.3). Six percent
of patients (189) were MRD-HR: EFS 50.1%
(4.1; P < .001). PCR-MRD discriminated
prognosis even on top of white blood cell
count, age, early response to prednisone,
and genotype. MRD response detected by
sensitive quantitative PCR at 2 predefined
TPs is highly predictive for relapse in child-
hood pB-ALL. The study is registered at
http://clinicaltrials.gov: NCT00430118 for
BFM and NCT00613457 for AIEOP. (Blood.
2010;115(16):3206-3214)
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Learning objectives
Upon completion of this activity, participants will be able to:
• Describe the currently accepted prognosis for pediatric acute lymphoblastic leukemia (ALL)
• List methods for assessing response to treatment of pediatric ALL
• Describe the 5-year risk for events associated with the standard-risk, intermediate-risk, and high-risk groups of minimal residual disease
• Identify the strongest prognostic factor for predicting outcomes in pediatric ALL
Introduction
Over the past 3 decades, remarkable advances have been achieved in the
treatment of acute lymphoblastic leukemia (ALL) in children.1-9 How-
ever, significant challenges still remain. In fact, although current
treatment strategies result in long-term remission for nearly 80% of
children with ALL, the remaining 20% ultimately relapse, and cure rate
after relapse is approximately 25% to 40%. Moreover, some subgroups
of children who now receive intensive therapy are likely to be
overtreated and may well be cured using less intensive regimens,
resulting in reduced toxicity and fewer long-term side effects.10-12
Besides risk factors associated with the patient (eg, sex, age at diagnosis)
and the disease (eg, white blood cell count at diagnosis, immunopheno-
type, structural and numeric chromosomal aberrations), measurement of
in vivo treatment effectiveness has proven to be most important in
predicting patient outcome and risk of relapse.4,13-18
Over the past 10 to 15 years, several techniques have been
developed to complement and refine morphology in assessing
response to treatment, including immunologic or molecular mark-
ers, fluorescent in situ hybridization, in vitro drug response, and
colony assays.19-24 This technologic advancement led to introduc-
ing the concept of minimal residual disease (MRD), which has
challenged the conventional definition of “remission.”25
Several studies on childhood and adult ALL, based mainly on
immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements as
polymerase chain reaction (PCR) targets for monitoring MRD, have
indicated that the detection of residual disease during initial cytotoxic
treatment can predict outcome.13,17,21 Groups collaborating in the
International Berlin-Frankfurt-Mu¨nster Study Group (I-BFM-SG) have
pioneered the evaluation of MRD by PCR in childhood ALL. MRD
assessment at days 33 and 78 of treatment by 2 clonal Ig/TCR markers,
with sensitivity of at least 104, identified 3 risk groups. MRD-based
stratification was superior to that based on other clinically relevant risk
factors, including age, blast count at diagnosis, and immunophenotype.13
The collaborative prospective Associazione Italiana di Ematolo-
gia Pediatrica and Berlin-Frankfurt-Mu¨nster (AIEOP-BFM ALL)
2000 study of childhood ALL (carried out in Austria, Germany,
Italy, and Switzerland) was based on these results. The laboratory
requirements and feasibility results of the MRD-directed risk
stratification using real-time, quantitative PCR analysis of Ig/TCR
gene rearrangements, as applied in this large multicenter prospec-
tive trial, have been recently published.19 In this paper, we report on
the clinical results, and the predictive value for relapse, of the
quantitative assessment of MRD in childhood B-cell precursor
ALL (pB-ALL), treated with the AIEOP-BFM ALL 2000 protocol.
Results in T-ALL will be reported separately.
Methods
Patients
From July 1 (September 1 forAIEOP) 2000 to July 31 (June 30 for BFM) 2006, a
total of 4741 patients with Philadelphia chromosome–negative (Ph) ALL, aged
between 1 and 18 years (infants younger than 1 year were eligible for a separate
protocol), were diagnosed in one of the 127 participating study centers and were
eligible for the study AIEOP-BFM ALL 2000. Of these patients, 4016 had Ph
pB-ALL and 3184 (79.3%) were stratified by MRD. Lack of material or of
sensitive MRD markers (n 772), early death (n 59), or relapse before day 78
(n 1) precluded the use of MRD for final patient stratification in the remaining
832 (20.7%) patients.19 Because a new specific protocol was opened for Ph
ALL subtype from 2004 onward, only 79 Ph ALL patients were recruited in
AIEOP-BFM ALL 2000; 54 were stratified by MRD and are here described as a
separate additional subgroup.
Diagnostic studies
Diagnosis of ALL was performed using cytomorphology (French-American-
British criteria) and cytochemistry when 25% or more lymphoblastic cells
were present in the bone marrow. Flow cytometric immunophenotyping
was performed according to consensus protocols based on the guidelines
proposed by the European Group for the Immunological Characterization
of Leukemias.26 Presence of TEL/AML1, BCR/ABL, and MLL/AF4 fusion
transcripts was screened as previously described.27
Complete remission (CR) was defined as the absence of physical signs
of leukemia or detectable leukemia cells on blood smears, a bone marrow
with active hematopoiesis and fewer than 5% leukemia blast cells, and
normal cerebrospinal fluid. Patients who did not achieve CR at the end of
induction phase IA were treated with phase IB of protocol I, and 3
subsequent high-risk (HR) blocks; resistance was defined as failure to
achieve CR by the end of the third HR block (supplemental Figure 1 and
supplemental Table 1 for protocol details, available on the Blood Web site;
see the Supplemental Materials link at the top of the online article).
Molecular marker identification and MRD analysis
The logistics of the study, cell sample isolation, and identification of the markers
for MRD evaluation have been recently reported.19 Briefly, DNA samples
obtained at diagnosis were screened by PCR amplification using the BIOMED-1
primer sets for Ig kappa deleting element gene rearrangements, IGK-Kde
(Vk-Kde, intron-Kde), complete and incomplete TCR delta (TCRD; Vd-(Dd)-
Jd1, Dd2-Jd1, Vd2-Dd3, Dd2-Dd3), and TCR gamma (TCRG; Vg-Jg1.3/2.3,
Vg-Jg1.1/2.1) rearrangements.28 Complete and incomplete IGH rearrangements
(VH-(DH)-JH, DH-JH) were identified using 5 VH and 7 DH family primers in
combination with 1 JH consensus primer,29,30 whereas for incomplete and
complete TCR beta (TCRB; D-J and V-D-J) and IGK (V-J) rearrange-
ments, the respective BIOMED-2 multiplex PCR primer sets were used.31
Junctional regions of clonal PCR products were sequenced, and
patient-specific junctional region sequences of potential PCR-MRD targets
were identified.19 Allele-specific oligonucleotide primers were designed
complementary to the junctional region sequence of each target, either
manually or using the Primer Express software (Applied Biosystems).
PCR-MRD targets were tested for specificity and sensitivity with the
aim for each patient to select 2 targets with a sensitivity of at least 104 and
a quantitative range of at least 104 for one target and at least 5 104 for
the second target.32 Quantitative reverse-transcription–PCR analysis was
performed and interpreted according to the guidelines developed within the
European Study Group for MRD detection in ALL (ESG-MRD ALL).32
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Risk group definitions and final stratification
Patients were defined as MRD standard risk (MRD-SR) if MRD was found to be
negative at both days 33 (time point 1 [TP1]) and 78 (TP2), using at least
2 molecular markers with sensitivity of 104 or less.17 If MRD levels differed
between the 2 markers, the highest MRD level was chosen for the final MRD
assessment. Patients were considered to be MRD intermediate risk (MRD-IR)
when MRD was positive at 1 or both TPs but at a level of less than 103 at TP2
with at least 2 markers. Patients with MRD 103 or more at TP2 were defined
MRD high risk (MRD-HR), independent of the sensitivity and the number of
markers. Patients with prednisone poor response (PPR;  1000 leukemic blasts
per microliter in the peripheral blood on day 8) or failure to achieve remission (ie,
with 5% leukemic blasts in the bone marrow on day 33, or persistent extramed-
ullary disease) after induction phase IA (induction failure) or positivity for
MLL/AF4 fusion transcript were treated in the HR arm irrespective of their MRD
results. If MRD evaluation was not available, patients were assigned to the IR
group or, based on clinical parameters, to the HR group; these patients are not part
of this report.
Treatment protocol
All enrolled patients were treated according to theAIEOP-BFMALL 2000 study
protocol: treatment outlines, details, and differences between AIEOP and BFM
are shown in supplemental Figure 1 and supplemental Table 1. The ethics
committee of each participating organization approved the study protocol.
Induction and consolidation phase. All patients underwent 7 days of
prephase with steroid therapy (prednisone) and 1 intrathecal dose of
methotrexate (intrathecal MTX), followed by induction phase IA and
induction consolidation phase IB; from day 8, patients were randomized to
continue steroid treatment with either prednisone (60 mg/m2 per day) or
dexamethasone (10 mg/m2 per day) until day 28 with subsequent tapering
of dose in 1 more week.
Protocol M and reinduction phases. SR and IR patients received 4 cycles
of high-dose MTX (HD-MTX, 5 g/m2); AIEOP patients with non–T ALL and
without central nervous system (CNS) or testicular involvement at diagnosis
received 2 g/m2. At the beginning of the reinduction phase, patients were
randomized to receive either protocol II or reduced-intensity protocol III in SR
group, or protocol II versus reduced-intensity protocol III given twice in the IR
group. HR patients were randomized to receive 3 blocks of non–cross-resistant
drugs followed by protocol III given 3 times versus 3 blocks followed by protocol
II given twice in the AIEOP group, or 6 blocks followed by protocol II in the
BFM group.
Maintenance therapy. Maintenance therapy consisted of daily 6-mer-
captopurine together with weekly MTX until 24 months from diagnosis.
CNS-directed therapy. CNS-directed therapy consisted of repeated
intrathecal MTX administration during each treatment phase. Only patients
who were treated in AIEOP centers and who did not undergo irradiation
received MTX treatment also during the continuation phase. Cranial
radiotherapy was given (dosage by age; supplemental Table 1) to patients at
HR or with CNS involvement at diagnosis.
Statistical analysis
Event-free survival (EFS) and survival times were calculated from date of
diagnosis to date of event, which, for EFS, was resistance, relapse, death, or
second neoplasm, whichever occurred first, and, for survival, death from any
cause. Of note, stratification by MRD is possible, by definition, only on the
subpopulation of patients who are failure-free by TP2. EFS and survival curves
were estimated according to Kaplan-Meier with Greenwood standard error,
always indicated in parentheses, and compared according to log-rank test.
Cumulative incidence curves for relapse were estimated adjusting for competing
risks of other events and were compared with the Gray test. The Cox model, after
stratification by group (AIEOP and BFM), was used to analyze the prognostic
role of PCR-MRD in terms of cause-specific hazard of relapse.33 A 1-step
multivariate model that included the most frequently used conventional prognos-
tic features was applied. The proportional hazard assumption was tested by
graphic checks. Tests were 2-sided, with .05 significance level. Analyses were
carried out using SAS 9.1.
The study is registered at the US National Institutes of Health website
http://clinicaltrials.gov as “Combination Chemotherapy Based on Risk of
Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia”
with the protocol identification number NCT00430118 for BFM and
NCT00613457 for AIEOP.
Results
The cohort of 4016 children between 1 and 18 years of age with
newly diagnosed Ph pB-ALL, enrolled in the AIEOP-BFM ALL
2000 study, had a 7-year EFS (standard error [SE]) and survival
(SE) of 80.4% (0.9) and 91.8% (0.5), respectively.
The 3184 children stratified by MRD had, by definition, completed
induction phase IA (TP1) and induction consolidation phase IB (TP2).
This report focuses only on these patients, alive at TP2 (day78).
Their overall 7-year estimates for EFS (SE) and survival (SE)
were 80.7% (1.0) and 92.8% (0.6), respectively, with a median
follow-up of 4.0 years (supplemental Figure 2). The 7-year EFS
and survival were 77.4% (1.6) and 92.0% (0.9) for 1329 AIEOP
patients vs 83.0% (1.3) and 93.4% (0.7) for 1855 BFM patients,
respectively. The difference in EFS was consistent in all subgroups
of patients stratified by MRD, and the impact of PCR-MRD was
found to be the same in AIEOP and BFM centers. The presented
analyses will therefore concern the whole cohort of patients
recruited by the 2 groups and stratified by MRD.
Among the 3184 patients, 42% were MRD-SR, 52% MRD-IR,
and 6% MRD-HR; they had a significantly different outcome, with
5-year EFS estimates of 92.3% (0.9), 77.6% (1.3), and 50.1 (4.1),
respectively (Figure 1A). The 5-year survival estimates were
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Figure 1. Event-free survival (A) and cumulative incidence of relapse (B)
according to PCR-MRD classification in 3184 pB-ALL patients.
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97.8% (0.5), 93.4% (0.7), and 60.8 (4.0), respectively. Types of
event are reported in Table 1; 43 patients died in CR (17 of them
after stem cell transplantation [SCT] in first CR) and 22 (5-year
cumulative incidence 0.8% [0.2]) had a secondary neoplasm. Most
events were relapses and the 5-year cumulative incidence was
markedly different according to the group of risk by MRD: 6.0%
(0.8) for MRD-SR, 21.0% (1.2) for MRD-IR, and 34.9% (3.8) for
MRD-HR patients (Figure 1B).
The distribution of disease and patient characteristics by
PCR-MRD stratification is shown in Table 2. Patients with
hyperleukocytosis (white blood cell [WBC] count  100109/L)
or PPR had higher probability of being MRD-HR. However, the
MRD-SR group comprised rather large proportions of patients
from subsets conventionally considered at high risk, namely those
with WBC count 100109/L or higher and age 10 years or older.
The distribution by MRD among patients who, by National Cancer
Institute criteria,34 were at standard risk (MRD-SR, 45.3%; IR,
50.5%; HR, 4.3%) or at high risk (MRD-SR, 35.5%; IR, 54.7%;
HR, 9.8%) confirms this observation.
In each subgroup described in Table 2, patients had significantly
different EFS by MRD levels (P  .001).
According to AIEOP-BFM ALL 2000 final stratification,
167 patients were allocated to HR treatment (because of PPR or
MLL/AF4 fusion or no CR at day 33), although their MRD was
at SR (n  37) or IR (n 130). Interestingly, the outcome of these
patients was favorable: the 5-year EFS of 92.2% (5.6) for those
with MRD-SR and 77.4% (4.3) for those with MRD-IR shows that
MRD diagnostics discriminates prognostic subgroups on top of
classical HR criteria.
Figure 2 shows the prognostic value of MRD in subgroups
defined by genetic features. In TEL/AML1-positive patients
(n  762; 25.9% of pB-ALL), high levels of MRD at TP2 were
rarely detected (n 10; 1.3%); yet MRD was able to stratify the
remaining patients in 2 large subgroups (57.7% MRD-SR; 40.9%
MRD-IR) with significantly different outcomes (Figure 2A). Simi-
lar results were obtained in patients with favorable DNA index
( 1.16 and 1.6): MRD-HR patients were rare (1.4%); MRD-SR
and IR patients had significantly different outcome (Figure 2B).
Fifty-four Ph ALL patients treated in our study and stratified
by MRD are here analyzed separately, as it is of major interest to
evaluate whether MRD response discriminates outcome also in
these patients who are generally considered to have a dismal
prognosis.35,36 Ph patients enrolled in the AIEOP-BFM ALL 2000
study were allocated to the high-risk treatment arm and had a
markedly different outcome according to MRD (Figure 2C). In
more detail, 8 patients (14.8%) were MRD-SR: 6 of them remained
in continuous complete remission (CCR) (3 after SCT), 1 died in
CCR, and 1 relapsed at 2.7 years from diagnosis; 24 (44.4%) were
MRD-IR: 16 remained in CCR (13 after SCT), 1 died in CCR, 2
died because of treatment-related complications after SCT, and 5
relapsed after 0.6 to 5.1 years; 22 (40.8%) were MRD-HR and only
4 remained in CCR (all after SCT), 1 died in CCR, 6 died from
treatment related mortality after SCT and 11 relapsed. Of note,
MRD identified, even within the Ph ALL prednisone good-
response subgroup (n 41), patients at very high risk of relapse
(MRD-HR, n 11, 5 relapses, 4 deaths).
Superiority of PCR-MRD over conventional stratification criteria
can also be shown by evaluating its impact in patients of the AIEOP-
BFM ALL 2000 study after stratifying them according to the BFM 95
criteria6 (based on age, WBC count, early morphologic response, and
clonal translocations; Table 2). Patients (3% and 4.8%, respectively) at
standard and medium risk by BFM 95 criteria were MRD-HR, and these
patients had an unfavorable prognosis (Figure 3A-B). Furthermore,
49.7% of patients at standard risk by BFM 95 criteria (Figure 3A)
presented a slower MRD clearance (MRD-IR) and had a significantly
inferior outcome compared with MRD-SR patients (P .001). Con-
versely, early MRD negativity among patients at medium risk by BFM
95 stratification criteria (Figure 3B) identified a major subset (42.4%)
with excellent prognosis. Interestingly, patients at high risk by BFM 95
criteria (Figure 3C), most of them with PPR, also could be clearly
stratified by MRD, and 15.6% with early clearance of residual disease
had an excellent outcome.
The dynamics of MRD clearance at TP1 and TP2 and its relation to
the distribution of relapses in pB-ALL are shown in supplemental Table
2. By single time point, 44% of the patients (1399/3176) were MRD
negative at TP1, with a 6.3% (0.8) 5-year cumulative incidence of
relapse. A higher proportion of patients (77%) was MRD negative
(2470/3176) at TP2, with a 10.6% (0.8) 5-year cumulative incidence of
relapse. The incidence of relapse in patients (1777/3176) who did not
clear their disease at TP1 depends on TP2 MRD level, especially in
those with high ( 103) TP1 levels.As shown in Figure 4, 257 patients
with high MRD levels at TP1 but no detectable MRD by TP2 had a
Table 1. Distribution of events in pB ALL Ph patients according to MRD classification
MRD-SR MRD-IR MRD-HR Total
No. % No. % No. % No. %
Total 1348 42.3 1647 51.7 189 5.9 3184
Resistant* 0 0 3 1.6 3 0.1
Relapses 61 4.5 266 16.2 60 31.7 387 12.1
Bone marrow 32 2.4 168 10.2 49 25.9 249 7.8
Central nervous system 9 0.6 29 1.8 1 0.5 39 1.2
Testis 7 0.5 21 1.3 1 0.5 29 0.9
Bone marrow other 12 0.9 41 2.5 8 4.3 61 1.9
Other 1 0.1 7 0.4 1 0.5 9 0.3
Death in CCR 10 0.7 13 0.8 20 10.6 43 1.4
After chemotherapy 10 0.7 10 0.6 6 3.2 26 0.8
After stem cell transplantation 0 3 0.2 14 7.4 17 0.6
Second malignant neoplasm† 10 0.7 9 0.5 3 1.6 22 0.7
CCR 1267 94.1 1359 82.5 103 54.5 2729 85.7
Only patients alive by TP2 are included in this cohort and consequently induction deaths in protocols IA and IB are not included.
ALL indicates acute lymphoblastic leukemia; MRD, minimal residual disease; SR, standard risk; IR, intermediate risk; HR, high risk; and CCR, continuous complete
remission.
*Resistant patients are those who did not achieve CR by the end of the third HR block of chemotherapy.
†Acute myeloid leukemia (n  9), myelodysplastic syndrome (n  8), non-Hodgkin lymphoma (n  1), glioblastoma (n  1), brain tumor (n  2), and other tumor (n  1)
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5-year cumulative incidence of relapse of 20.7% (2.9), compared with
40.7% (3.0) in patients with MRD still positive but at a level less than
103 at TP2 (P .001).
Results obtained by applying the Cox model to single character-
istics (univariate analysis) are contrasted to those obtained in the
multivariate analysis (Table 3). Except for the increased risk of
relapse in PPR patients, which is not significant (hazard ra-
tio  1.37, 95% confidence interval 0.95-1.99), all other charac-
teristics affect the hazard of relapse significantly. In particular,
PCR-MRD has by far the strongest prognostic value, with a 4-fold
and 9-fold increase in relapse rate for IR and HR, respectively,
compared with SR levels.
The multivariate analysis confirms the prognostic value of
PCR-MRD and shows that WBC count, TEL/AML1 status, and
DNA index retain independent significant impact on the hazard of
relapse. Interestingly, PPR is now associated with a borderline
significant lower risk of relapse. For the interpretation of these
results, many aspects should be considered. First, PPR (compared
with prednisone good responders [PGR]) is still related to a higher
probability of having PCR-MRD HR levels (Table 2), which
explains the higher relapse rate in univariate analysis (Table 3).
However, Kaplan-Meier analysis (Table 2) shows that PPR com-
pletely loses its adverse prognostic value if compared with PGRs
who have the same PCR-MRD levels (SR, IR, HR). This is not true,
for instance, for higher WBC counts, which, within the same
PCR-MRD levels, still retain a worse outcome (Table 2). In the
multivariate Cox model, the paradoxical result of a protective
effect of PPR comes from adjusting for PCR-MRD, as well as for
other features. Finally, it should also be considered that PPR is the
only feature, among those included in the Cox model that, besides
PCR-MRD, qualifies patients for the most intensive treatment arm,
which evidently plays a role in improving these patients’ outcome.
Discussion
AIEOP-BFM ALL 2000 is the first, large-scale, prospective clinical
trial inALL in which PCR-MRD measured at 2 time points, days 33 and
Table 2. Clinical and biological features and related outcome (event-free survival [EFS] estimated at 5 years from diagnosis) in pB-ALL Ph
patients according to MRD classification
MRD-SR MRD-IR MRD-HR
Total, no.No. (%) 5-y EFS (SE) No. (%) 5-y EFS (SE) No. (%) 5-y EFS (SE)
Total 1348 (42.3) 92.3 (0.9) 1647 (51.7) 77.6 (1.3) 189 (5.9) 50.1 (4.1) 3184
Sex
Male 684 (40.8) 92.3 (1.2) 883 (52.7) 74.9 (1.8) 109 (6.5) 43.5 (5.3) 1676
Female 664 (44.0) 92.3 (1.3) 764 (50.7) 80.7 (1.7) 80 (5.3) 59.1 (6.4) 1508
Age, y
1-9 1165 (45.0) 93.5 (0.9) 1298 (81.7) 79.0 (1.4) 126 (7.9) 50.2 (5.2) 2589
10-17 183 (30.8) 84.4 (3.4) 349 (58.7) 72.3 (2.9) 63 (10.6) 50.3 (6.7) 595
WBC count,109/L
Lower than 50 1174 (43.1) 92.9 (0.9) 1416 (51.9) 79.3 (1.3) 137 (5.0) 49.7 (5.0) 2727
50-100 104 (39.1) 89.6 (3.3) 137 (51.5) 71.3 (4.5) 25 (9.4) 55.4 (10.1) 266
100 or higher 70 (36.7) 86.1 (4.8) 94 (49.2) 60.7 (6.0) 27 (14.1) 46.6 (9.9) 191
NCI criteria*
Standard 1007 (45.3) 94.1 (0.9) 1122 (50.5) 80.3 (1.5) 95 (4.3) 49.3 (6.1) 2224
High 341 (35.5) 86.9 (2.2) 525 (54.7) 71.8 (2.4) 94 (9.8) 51.4 (5.4) 960
TEL/AML1
Negative 801 (36.8) 90.6 (1.3) 1204 (55.4) 76.1 (1.5) 169 (7.8) 51.1 (4.4) 2174
Positive 440 (57.7) 94.9 (1.2) 312 (40.9) 81.7 (2.8) 10 (1.3) 54.9 (17.2) 762
Not known 107 (43.2) 94.1 (2.6) 131 (52.8) 80.8 (4.4) 10 (4.0) 30.0 (14.5) 248
DNA index
1.16 or more and less than 1.6 218 (44.8) 93.7 (2.1) 262 (53.8) 79.8 (3.1) 7 (1.4) 487
Less than 1.16 or 1.6 or more 814 (40.9) 91.4 (1.2) 1022 (51.3) 74.9 (1.7) 155 (7.8) 52.1 (4.6) 1991
Not known 316 (44.8) 93.8 (1.6) 363 (51.4) 83.4 (2.3) 27 (3.8) 39.2 (10.4) 706
Response to prednisone
Prednisone good responders 1310 (44.1) 92.3 (0.9) 1524 (51.3) 77.6 (1.3) 138 (4.6) 50.3 (4.9) 2972
Prednisone poor responders 36 (17.9) 91.8 (5.9) 116 (57.7) 79.2 (4.5) 49 (24.4) 50.5 (7.7) 201
Not known 2 (18.2) 7 (63.6) 2 (18.2) 11
BFM 95 criteria†
Standard 597 (47.3) 94.0 (1.2) 628 (49.7) 83.8 (1.8) 38 (3.0) 42.9 (9.6) 1263
Medium 714 (42.4) 90.9 (1.3) 889 (52.8) 73.3 (1.8) 81 (4.8) 56.2 (6.2) 1684
High 37 (15.6) 92.2 (5.6) 130 (54.9) 77.4 (4.3) 70 (29.5) 47.3 (6.4) 237
Final stratification AIEOP-BFM 2000
Standard 1311 (100.0) 92.3 (0.9) 0 0 1311
Intermediate 0 1517 (100.0) 77.6 (1.3) 0 1517
High 37‡ (10.4) 92.2 (5.6) 130§ (36.5) 77.4 (4.3) 189 (53.1) 50.1 (4.1) 356
MRD affected outcome significantly (at the .001 level) in every subgroup.
ALL indicates acute lymphoblastic leukemia; MRD, minimal residual disease; SR, standard risk; IR, intermediate risk; HR, high risk; SE, standard error; WBC white blood
cell; NCI, National Cancer Institute; BFM, Berlin-Frankfurt-Mu¨nster; and AIEOP, Associazione Italiana di Ematologia Oncologia Pediatrica.
*Standard: age 1-9 years and WBC 50 000; high: age 10 years or WBC 50 000.
†High: PPR or no remission on day33 or t(4;11); medium: no high-risk criteria, WBC 20 000 or age 6 years or T-ALL; standard: no high-risk criteria, WBC 20 000
and age between 1 and 6 years and no T-ALL.
‡These patients were at high risk for no CR day33 (n  1) or PPR (n  36).
§These patients were at high risk for no CR day33 (n  8) or MLL/AF4 fusion transcript (n  8) or PPR (n  114).
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78 of treatment, was used to classify patients into MRD-SR,
MRD-IR, or MRD-HR groups and thus to determine postinduction
treatment. MRD-based treatment tailoring and results of randomiza-
tions in AIEOP-BFM 2000, not reported here, do not change the
most important message of this work, namely that MRD response
discriminates within risk groups defined by traditional features.
Results reported here on PCR-MRD confirm those obtained in
the pilot I-BFM-SG MRD study 91,13 except for an improvement
of the outcome in the MRD-HR group. This better outcome was
due to an intensification of treatment as already shown in AIEOP
ALL 95 and ALL-BFM 95 studies.6,13,37-39
Besides MRD-HR patients, those presenting the chromosomal
translocations t(4;11) and t(9;22), or PPR, or not reaching CR at the
end of induction were treated as HR regardless of the PCR-MRD
findings. Postinduction treatment in other patients (SR or IR) was
determined only by MRD response. In this context, MRD measure-
ment by PCR retained its ability to discriminate prognosis in
pB-ALL. This was consistently observed in each subgroup defined
by the most relevant initial presenting features, either favorable or
unfavorable, such as WBC count, age, and prednisone response.
PCR-MRD discriminated distinct prognostic groups also in the
2 largest genetic subsets of pediatric pB-ALL, that is, the TEL/
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Figure 2. Prognostic impact of PCR-MRD in 762 TEL/AML1-positive patients
(A), in 487 patients with favorable DNA index (> 1.16 and < 1.6; B), and in
54 Ph patients (C).
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Figure 3. Prognostic impact of PCR-MRD in 3184 pB-ALL patients (Ph) within
subgroups according to ALL-BFM 95 criteria: standard (1263 patients; A),
medium (1684 patients; B), and high (237 patients; C).
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AML1-positive subgroup and the hyperdiploid subgroup, and in
the rare Ph ALL subtype, which is generally considered to be
associated with a very poor prognosis.
Data presented here on a very large cohort of pB-ALL patients
(n  3184) clearly show the superiority of PCR-MRD over more
conventional stratification criteria in identifying 3 risk groups, with
very different prognosis. Subgroups of patients who would be
qualified as standard, medium, or high risk by BFM-95 stratifica-
tion criteria (WBC count, age, response to prednisone or to
induction phase IA, and the t(4;11) or t(9;22) chromosomal
translocations)6 can easily be discriminated into 3 new risk groups
by MRD measured at 2 time points. The same pattern is observed
within ALL National Cancer Institute subgroups.34
Results reported here confirm that, in pB-ALL, MRD negativity
at the end of induction (TP1) is the strongest predictor for excellent
outcome (5-year EFS 90%)40-44; therefore, in the future, it might
be difficult to plan randomized studies to improve outcome in
MRD-SR patients.
Interestingly, among 1358 MRD-SR patients, only 61 relapsed,
and 29 of them presented with an extramedullary either isolated
(n  17) or combined (n 12) relapse, which may be, especially
for the isolated ones, not likely to be predicted by bone marrow
MRD response. High levels of MRD at TP2 are predictive for poor
outcome (5-year EFS  50%), with a 5-year cumulative incidence
of relapse (SE) of 27.8% (4.7) and 43.5% (6.4) in patients
presenting PCR-MRD levels of 103 or more than 103, respec-
tively (supplemental Table 2). Interestingly, however, whereas
among patients presenting high MRD levels at TP1, those with no
PCR-MRD detectable at TP2 had a favorable outcome, those with
PCR-MRD still present at TP2 had a marked increase in the risk of
relapse (Figure 4). These findings show that TP2 PCR-MRD levels
are very important in tailoring treatment in patients with high
PCR-MRD levels at TP1. In the multivariate analysis (Table 3),
PCR-MRD is, by far, the most relevant factor discriminating
prognosis. It overshadows the importance of other known prognos-
tic features, although WBC count at diagnosis, TEL/AML1 status,
and DNA index retain independent value. Noticeably, PPR appears
associated with a decreased hazard of relapse, which makes sense
only considering that all PPR patients were allocated to HR
treatment, regardless of any other features. Although the MRD
prognostic value is also therapy dependent, in our opinion these
results may provide some hints for other studies, too. A favorable
prognosis in all patients with fast clearance of MRD (ie, MRD
negative after 5 weeks of therapy) can be demonstrated indepen-
dent of their non–MRD-related risk features. This suggests that in
patients undergoing relatively intensive treatment, such as that of
the AIEOP-BFM ALL 2000 study, SCT may not be indicated even
in the presence of any other combination of adverse prognostic
features (or risk factors) if the MRD response proved to be
favorable. On the other hand, for patients with poor MRD response
(ie, MRD  103 after 2 months of therapy) despite rather
favorable non-MRD risk criteria, treatment intensification also
comprising SCT may be indicated to compensate for the MRD-
derived high relapse risk. MRD response in pB-ALL could thus
Table 3. Results of the univariate and multivariate analyses
Univariate analysis Multivariate analysis
Hazard ratio 95% CI P Hazard ratio 95% CI P
Age, y
1-9 1 1
10-17 1.68 1.32-2.14  .001 1.17 0.91-1.51 .21
WBC count,109/L
Lower than 50 1 1
50-100 1.60 1.16-2.21 .004 1.55 1.11-2.15 .009
100 or higher 2.41 1.73-3.34  .001 2.10 1.49-2.96  .001
TEL/AML1*
Negative 1 1
Positive 0.47 0.35-0.63  .001 0.59 0.43-0.81  .001
DNA index
Less than 1.16 or 1.6 or more 1 1
1.16 or more and less than 1.6 0.59 0.42-0.82 .002 0.62 0.44-0.88 .008
Missing 0.80 0.59-1.07 .13 0.91 0.67-1.22 .52
Response to prednisone
Prednisone good responder 1 1
Prednisone poor responder 1.37 0.95-1.99 .09 0.66 0.44-0.98 .04
PCR-MRD
MRD-SR 1 1
MRD-IR 3.83 2.86-5.12  .001 3.54 2.64-4.75  .001
MRD-HR 9.47 6.51-13.78  .001 7.51 5.06-11.15  .001
Cox model stratified by group (AIEOP and BFM) on hazard of relapse in 2927 pB-ALL (Ph) patients (with 354 relapses) for whom information on most covariates was
available.
CI indicates confidence interval; WBC, whtie blood cell; PCR-MRD, polymerase chain reaction minimal residual disease; SR, standard risk; IR, intermediate risk; and HR,
high risk.
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Figure 4. Prognostic value of TP1 and TP2 in 1777 non–MRD-HR patients (ie,
patients with MRD< 103 at TP2) who are MRD positive at TP1.
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indeed be crucial in designing an algorithm on some therapeutic
elements: we think, for example, that all CNS-negative patients
who do not have a poor MRD response could be spared CNS
radiotherapy. Treatment intensification could also be planned for
patients with slow clearance of their disease (ie, MRD still
detectable after 2 months of therapy) particularly if levels of MRD
were high 4 or 5 weeks after diagnosis. Reduction of treatment
intensity instead, in our opinion, should be performed only under
controlled conditions. Such MRD-based risk algorithms are, how-
ever, still to some extent treatment dependent, and cannot univer-
sally be applied in every available ALL treatment regimen.
Measurement of MRD is widely applied in contemporary
childhood ALL studies. The technologies used may be either
molecular or flow cytometric (FCM) and these 2 approaches may
differ for sensitivity, specificity, costs, reproducibility, and feasibility.45
Standardization, reproducibility, and quality control among different
laboratories are absolutely necessary for both methodologies.32
In our study, we used very strict criteria for patient stratification
(at least 2 targets with a sensitivity of at least 104).19,22,32 However,
if we analyze data of patients excluded from the present report
because they had only 1 sensitive marker available (n 454),
results are very similar to those of patients stratified by 2 sensitive
markers, with a 5-year EFS of 94.1% (1.6) and of 83.3% (3.3),
respectively, in patients who were MRD-SR (n 294) or IR
(n  160) by 1 marker. Only 1 sensitive PCR-MRD marker may
thus be adequate and may allow stratification of more than 90% of
the patients. Accordingly, in the AIEOP-BFM ALL 2009 study, 1
marker will be considered sufficient to stratify patients by PCR-
MRD in patients lacking a second one.
The choice of the MRD methodology for a childhood ALL
study depends largely on the aims of the study and resources
available. The 2 methodologies (eg, molecular biology and flow
cytometry) could in fact also be used in a complementary fashion
for different aims within the same study. As recently shown in a
study conducted by AIEOP,46 measurement of FCM-MRD on bone
marrow samples collected on day 15, as already suggested by
PCR-MRD findings at day 15,47 may allow identification of very
early responders ( 0.1% blast cells), who may benefit from
treatment reduction, as well as a small subset of patients with high
MRD levels ( 10% blast cells) who have a poor prognosis
independent of PCR-MRD response and could thus benefit from
treatment intensification. Accordingly, in the AIEOP-BFM ALL
2009 study, these 2 groups of patients will be eligible for a
randomized treatment reduction study and for HR treatment,
respectively.
The main finding of the present study is that MRD response in
pB-ALL detected by highly sensitive and well-standardized PCR
technique is highly predictive of relapse, thus reducing markedly
the importance of conventional prognostic factors such as age,
WBC count at diagnosis, genetic abnormalities, and also pred-
nisone response. Yet, further stratification in prognostic subgroups
for tailoring treatment intensity can be considered. In this regard,
future AIEOP-BFM strategy will adopt more extensively the
concept of MRD early response, combining FCM- and PCR-MRD
evaluation, also taking biologic subgroups into consideration.
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